Equities Analysts Offer Predictions for Insulet Corporation’s Q1 2018 Earnings (PODD)
Insulet Corporation (NASDAQ:PODD) – Investment analysts at Jefferies Group issued their Q1 2018 earnings per share (EPS) estimates for shares of Insulet Corporation in a report released on Thursday. Jefferies Group analyst R. Denhoy forecasts that the medical instruments supplier will post earnings of ($0.09) per share for the quarter. Jefferies Group has a “Buy” rating and a $48.00 price objective on the stock. Jefferies Group also issued estimates for Insulet Corporation’s Q2 2018 earnings at ($0.06) EPS and FY2018 earnings at $0.13 EPS.
A number of other equities research analysts have also issued reports on the company. ValuEngine upgraded Insulet Corporation from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Piper Jaffray Companies restated an “overweight” rating and issued a $47.00 price target on shares of Insulet Corporation in a research report on Monday, May 22nd. Canaccord Genuity restated a “hold” rating and issued a $50.00 price target (up from $42.00) on shares of Insulet Corporation in a research report on Tuesday, July 11th. BidaskClub upgraded Insulet Corporation from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, June 27th. Finally, Cowen and Company restated a “buy” rating and issued a $52.00 price target on shares of Insulet Corporation in a research report on Friday, July 14th. Eight investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $49.69.
WARNING: “Equities Analysts Offer Predictions for Insulet Corporation’s Q1 2018 Earnings (PODD)” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/07/equities-analysts-offer-predictions-for-insulet-corporations-q1-2018-earnings-podd.html.
Shares of Insulet Corporation (NASDAQ PODD) opened at 53.65 on Monday. Insulet Corporation has a 1-year low of $30.69 and a 1-year high of $55.46. The company’s market capitalization is $3.11 billion. The stock has a 50 day moving average price of $50.00 and a 200 day moving average price of $44.62.
Insulet Corporation (NASDAQ:PODD) last released its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported ($0.13) earnings per share for the quarter, meeting the consensus estimate of ($0.13). The business had revenue of $110 million during the quarter, compared to analysts’ expectations of $106.23 million. Insulet Corporation had a negative return on equity of 46.88% and a negative net margin of 7.30%. The firm’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.08) EPS.
In other Insulet Corporation news, EVP Bradley A. Thomas acquired 3,000 shares of the stock in a transaction that occurred on Thursday, May 11th. The stock was bought at an average cost of $38.69 per share, for a total transaction of $116,070.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jessica Hopfield acquired 2,580 shares of the stock in a transaction that occurred on Thursday, May 11th. The stock was acquired at an average price of $38.68 per share, with a total value of $99,794.40. The disclosure for this purchase can be found here. Insiders purchased 8,080 shares of company stock valued at $317,339 over the last quarter. 2.60% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Marshall Wace North America L.P. acquired a new position in shares of Insulet Corporation during the second quarter valued at $8,882,000. Turner Investments LLC acquired a new position in shares of Insulet Corporation during the second quarter valued at $334,000. Frontier Capital Management Co. LLC raised its position in shares of Insulet Corporation by 2.8% in the second quarter. Frontier Capital Management Co. LLC now owns 1,809,473 shares of the medical instruments supplier’s stock valued at $92,844,000 after buying an additional 50,019 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in shares of Insulet Corporation by 407.3% in the second quarter. BNP Paribas Arbitrage SA now owns 7,797 shares of the medical instruments supplier’s stock valued at $400,000 after buying an additional 6,260 shares during the last quarter. Finally, Legal & General Group Plc raised its position in shares of Insulet Corporation by 1.9% in the second quarter. Legal & General Group Plc now owns 20,233 shares of the medical instruments supplier’s stock valued at $1,034,000 after buying an additional 376 shares during the last quarter.
About Insulet Corporation
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.